# Kiora Pharmaceuticals Inc. (KPRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $11M  
**Price:** $2.60 (-1.14%)

> Kiora Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing therapies for eye disease. The company primarily works on innovative treatments aimed at addressing unmet medical needs in ophthalmology. Their research and product development are directed towards advancing therapies that can combat vision-related ailments such as eye inflammation and retinal diseases. By specializing in niche and complex eye conditions, Kiora Pharmaceuticals impacts the biotechnology and healthcare sectors, offering potential breakthroughs and improvements in treatment options. The company's commitment to biotechnology innovation provides vital contributions to therapeutic development within the pharmaceutical landscape, emphasizing targeted, patient-centric approaches in vision care.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$13M | -$11M | — |
| 2024 | $16M | — | $5M | $4M | — |
| 2023 | — | — | -$13M | -$13M | — |
| 2021 | — | — | -$14M | -$14M | — |
| 2020 | $12,059 | — | -$7M | -$7M | — |
| 2019 | $3M | — | — | -$7M | — |
| 2018 | $2M | — | -$11M | -$11M | — |
| 2017 | $407,518 | — | — | -$13M | — |
| 2016 | $669,259 | — | — | — | — |
| 2015 | — | — | — | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $24M | $8M | $16M | $9M | — |
| 2024 | $36M | $11M | $26M | $4M | — |
| 2023 | $14M | $8M | $6M | $2M | — |
| 2021 | $20M | $6M | $15M | $8M | — |
| 2020 | $15M | $6M | $10M | $1M | $278,190 |
| 2019 | $10M | $3M | $7M | $4M | — |
| 2018 | $14M | $5M | $9M | $8M | — |
| 2017 | $14M | $16M | -$2M | $8M | — |
| 2016 | $10M | $10M | -$329,421 | $4M | — |
| 2015 | $10M | $3M | $6M | $8M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$10M | $110,789 | -$10M |
| 2024 | $9M | $6,256 | $9M |
| 2023 | -$10M | — | -$10M |
| 2022 | -$10M | — | -$10M |
| 2021 | -$11M | $63,865 | -$11M |
| 2020 | -$7M | $20,077 | -$7M |
| 2019 | -$8M | — | -$8M |
| 2018 | -$11M | $20,000 | -$11M |
| 2017 | -$6M | $36,999 | -$7M |
| 2016 | -$8M | — | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/KPRX)